39
Participants
Start Date
September 11, 2018
Primary Completion Date
March 30, 2026
Study Completion Date
March 30, 2026
Palbociclib
Taken at 100 mg once daily for 21 days, followed by 7 days off
Ibrutinib
560 mg taken orally all patients throughout the study
Weill Cornell Medical College, New York
Roswell Park Comprehensive Cancer Center, Buffalo
University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore
University of North Carolina, Chapel Hill
Medical University of South Carolina - Hollings Cancer Center, Charleston
Ohio State University, Columbus
St. Joseph Mercy Hospital Cancer Care Center, Ypsilanti
City of Hope National Medical Center, Duarte
Massachusetts General Hospital, Boston
Collaborators (1)
Pfizer
INDUSTRY
Alliance Foundation Trials, LLC.
OTHER